CACNA1G Protein - Cav3.1 T-type Calcium Channel

CACNA1G Protein (Cav3.1 T-type Calcium Channel)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Cav3.1 (T-type Calcium Channel Alpha-1G)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>T-type Calcium Channel Alpha-1G</td></tr>
<tr><td><strong>Gene</strong></td><td><a href="/genes/cacna1g">CACNA1G</a></td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/O43497" target="_blank">O43497</a></td></tr>
<tr><td><strong>Ion Channel Family</strong></td><td>Voltage-gated calcium channel (Cav3)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>262 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane (neuronal dendrites and soma)</td></tr>
<tr><td><strong>Protein Structure</strong></td><td>24 transmembrane segments, 4 domains</td></tr>
<tr><td><strong>Channel Type</strong></td><td>Low-voltage-activated (LVA)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a>, <a href="/wiki/sca42nd" style="color:#ef9a9a">SCA42ND</a>, <a href="/wiki/absence-seizures" style="color:#ef9a9a">absence seizures</a>, <a href="/wiki/intellectual-disability" style="color:#ef9a9a">intellectual disability</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">neurodegeneration</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-8d270062" style="co

CACNA1G Protein (Cav3.1 T-type Calcium Channel)

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Cav3.1 (T-type Calcium Channel Alpha-1G)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>T-type Calcium Channel Alpha-1G</td></tr>
<tr><td><strong>Gene</strong></td><td><a href="/genes/cacna1g">CACNA1G</a></td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/O43497" target="_blank">O43497</a></td></tr>
<tr><td><strong>Ion Channel Family</strong></td><td>Voltage-gated calcium channel (Cav3)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>262 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane (neuronal dendrites and soma)</td></tr>
<tr><td><strong>Protein Structure</strong></td><td>24 transmembrane segments, 4 domains</td></tr>
<tr><td><strong>Channel Type</strong></td><td>Low-voltage-activated (LVA)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">Alzheimer's Disease</a>, <a href="/wiki/sca42nd" style="color:#ef9a9a">SCA42ND</a>, <a href="/wiki/absence-seizures" style="color:#ef9a9a">absence seizures</a>, <a href="/wiki/intellectual-disability" style="color:#ef9a9a">intellectual disability</a>, <a href="/wiki/neurodegeneration" style="color:#ef9a9a">neurodegeneration</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-8d270062" style="color:#ce93d8" title="Score: 0.48">Sleep Spindle-Synaptic Plasticity Enhanc...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">51 edges</a></td>
</tr>
</table>
</div>

Overview

CACNA1G encodes the alpha-1G subunit of low-voltage-activated (LVA) T-type calcium channels, commonly known as Cav3.1. T-type calcium channels are unique among voltage-gated calcium channels in their ability to activate at relatively negative membrane potentials, making them crucial for neuronal pacemaking, burst firing, and thalamic oscillations[@perezreyes2003]. Cav3.1 is the principal T-type channel isoform in the thalamus and is widely expressed throughout the central nervous system, where it plays essential roles in sleep-wake cycles, sensory processing, and neuronal excitability regulation.

Dysregulation of Cav3.1 channel function has been implicated in multiple neurological disorders, including epilepsy, migraine, and neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD)[@Sheng2022]. The channel's unique gating properties—rapid activation and inactivation, and the ability to generate rebound low-threshold calcium spikes—make it a critical player in both normal neuronal function and pathological states.

Molecular Structure and Gating

Channel Architecture

Cav3.1 is a member of the voltage-gated calcium channel superfamily and shares the general architecture of these proteins[@catterall2000]:

Alpha-1 Subunit Structure:

• Four Homologous Domains (I-IV): Each domain contains six transmembrane segments (S1-S6)
• Voltage Sensor (S1-S4): The S4 segment contains positively charged arginine residues that sense membrane potential changes
• Pore Loop (between S5 and S6): Forms the ion selectivity filter
• C-terminal Regulatory Domain: Contains sites for modulation by kinases, neurotransmitters, and second messengers

• Different S6 segment architecture compared to high-voltage-activated (HVA) channels
• Faster activation kinetics at negative potentials
• Distinct inactivation mechanisms (both voltage-dependent and calcium-dependent)

Gating Properties

Cav3.1 exhibits distinctive gating characteristics[@Talavera2003]:

Energetics of Gating

The energetics of Cav3.1 gating involve[@Gomora2001]:

• Voltage dependence: The gating charge movement is approximately 12-14 elementary charges
• Activation energy: Relatively low energy barrier for channel opening
• Modulation by intracellular ions: Calcium and magnesium differentially affect channel inactivation

Normal Physiological Function

Neuronal Pacemaking

Cav3.1 channels play a critical role in spontaneous neuronal firing, particularly in thalamic neurons and certain cortical interneurons[@Dreyfus2010]:

• Low-threshold calcium spikes: Depolarization from hyperpolarized states triggers T-type channel opening, generating a burst of calcium influx
• Rebound firing: After inhibitory input, T-type channels drive rebound action potential generation
• Rhythmic oscillations: Cav3.1 contributes to delta wave generation during sleep and spindle-wave discharges

Thalamic Oscillations

In the thalamus, Cav3.1 is essential for[@huguenard1998]:

• Sleep spindles: Synchronized oscillations (7-14 Hz) characteristic of stage 2 sleep
• Delta waves: Slow-wave oscillations (0.5-4 Hz) during deep sleep
• Absence epilepsy: Pathological thalamocortical oscillations that manifest as spike-and-wave discharges

Sensory Processing

Cav3.1 channels contribute to sensory processing in various ways:

• Retinal signaling: Involved in rod and cone pathway processing
• Auditory processing: Modulates sound encoding in the inferior colliculus
• Somatosensory cortex: Influences tactile sensation integration

Dendritic Integration

Cav3.1 channels on dendritic shafts enable:

• Temporal summation: Facilitation of repetitive synaptic inputs
• Location-specific processing: Differential integration based on synapse location
• Back-propagation support: Aids in action potential propagation into dendrites

Role in Neurodegenerative Diseases

Alzheimer's Disease

Cav3.1 channel dysfunction contributes to several aspects of Alzheimer's disease pathology[@Cain2018]:

Calcium Dysregulation: AD is characterized by abnormal calcium signaling. T-type channels contribute to this through:

• Increased window current at depolarized membrane potentials
• Enhanced calcium influx during repetitive neuronal activity
• Amplification of amyloid-beta induced calcium dysregulation

• Upregulation of Cav3.1 in certain neuronal populations
• Reduced inactivation kinetics
• Increased channel density in early disease stages

• T-type channel blockers reduce calcium dysregulation
• Normalize neuronal firing patterns
• Protect against amyloid-beta toxicity

Parkinson's Disease

In Parkinson's disease, Cav3.1 plays a complex role in basal ganglia function[@Lu2015]:

Thalamic Dysfunction: PD affects thalamic oscillations through:

• Altered Cav3.1 expression in the thalamus
• Disrupted sleep-wake cycles
• Abnormal low-threshold spike bursts

• Cav3.1 modulation may contribute to therapeutic effects
• Frequency-dependent effects involve T-type channel gating

• D2 receptor activation reduces Cav3.1 currents
• Loss of dopaminergic input alters thalamic excitability

Epilepsy

Cav3.1 mutations cause or contribute to several epilepsy syndromes[@Ernst2019]:

Childhood Absence Epilepsy: Gain-of-function mutations in CACNA1G:

• Increased channel conductance
• Enhanced burst firing
• Lower threshold for thalamic oscillations

• Fever-induced channel dysfunction
• Hyperexcitability during hyperthermia

• Ethosuximide: Primary treatment for absence seizures
• Valproic acid: Broad-spectrum anticonvulsant
• Zonisamide: Newer T-type targeting agent

Migraine

Cav3.1 contributes to migraine pathophysiology:

• Cortical spreading depression initiation
• Thalamic pain processing
• Trigeminal nucleus caudalis activation

Signaling Pathways

Modulation by Second Messengers

Cav3.1 activity is modulated by multiple intracellular signaling pathways[@Chemin2002]:

Protein Kinase C (PKC):

• PKC phosphorylation reduces current amplitude
• Alters voltage dependence of activation

• Calcium-dependent inactivation via calmodulin
• Provides feedback regulation of calcium influx

• PKA phosphorylation increases current magnitude
• Modulates channel trafficking to the membrane

Interaction with Other Ion Channels

Cav3.1 interacts with various ion channels:

• HVA Calcium Channels: Cross-talk in calcium signaling
• Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels: Coordinated pacemaking
• Sodium channels: Co-localization in axon initial segments

Therapeutic Targeting

Clinical Applications

T-type calcium channels are therapeutic targets for[@Zamponi2020]:

Anticonvulsants:

• Ethosuximide: Primary mechanism is T-type (particularly Cav3.1/3.2) blockade
• Valproic Acid: Multiple mechanisms including T-type inhibition
• Zonisamide: Blocks T-type currents, useful for multiple seizure types

• Ethosuximide: Investigated for migraine prophylaxis
• Migrantat: T-type modulators in development

• Zonisamide: Approved for Parkinson's disease in Japan

Drug Development

Several approaches are being explored[@Cheong2023]:

Selective T-type Blockers:

• TTA-P2: Investigational selective T-type blocker
• Z944: Pan-T-type inhibitor with good brain penetration
• NNC 55-0396: Selective Cav3.1 antagonist

• Cav3.1-selective compounds for thalamic disorders
• Cav3.2-selective agents for peripheral applications

• Use-dependent blockers for pathological firing
• Enhanced affinity for inactivated states

Expression Patterns

Brain Regional Distribution

Cav3.1 is expressed throughout the brain[@Zhang2013]:

• Thalamus: Highest expression, particularly in relay neurons
• Cerebral Cortex: Layer 2/3 and layer 5 pyramidal neurons
• Cerebellum: Purkinje cells and deep cerebellar nuclei
• Basal Ganglia: Substantia nigra pars reticulata, globus pallidus
• Hippocampus: CA1 pyramidal cells and interneurons

Cell-Type Specificity

• Neurons: Primary expression in excitatory and inhibitory neurons
• Astrocytes: Low or absent expression
• Oligodendrocytes: Some expression in premyelinating stages
• Microglia: Not typically expressed

Mutations and Channelopathies

Disease-Causing Mutations

CACNA1G mutations are associated with several neurological conditions[@Huang2017]:

Gain-of-Function Mutations:

• Childhood absence epilepsy
• Febrile seizures plus
• Spinocerebellar ataxia

• Cardiac arrhythmias (in some cases)
• Neurodevelopmental disorders

Genotype-Phenotype Correlations

• Specific domain mutations correlate with disease phenotype
• S4 segment mutations often cause epilepsy
• C-terminal mutations may cause ataxia

See Also

• [CACNA1G Gene](/genes/cacna1g)
• [Calcium Channel Dysfunction](/mechanisms/calcium-channel-dysfunction)
• [Calcium Signaling Dysregulation](/mechanisms/calcium-signaling-dysregulation)
• [T-type Calcium Channels](/mechanisms/t-type-calcium-channels)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Epilepsy](/diseases/epilepsy)